1+ week, 6+ min ago   (433+ words) GSK gained rights to a Hutchmed antibody-targeted therapy conjugate, or ATTC. This new type of targeted therapy blocks two cancer-driving proteins and will initially be developed for lung, colorectal, and pancreatic cancers. GSK has experience with cancer therapies that use…...

1+ week, 2+ day ago   (401+ words) Ionis Pharmaceuticals’ zilganersen, brand name Zanvastro, is the first disease-modifying therapy approved for the neurological disorder Alexander disease. While Ionis has experience developing medicines for rare neuroscience indications, Zanvastro will be the first neurology product the company brings to the…...

1+ week, 6+ day ago   (351+ words) Faster trials are not a vanity metric. They reflect an undeniable need: getting safe therapies to patients sooner. Trials are dynamic systems, not linear projects We are taking a look at how health insurers are using AI, defining success, and…...

1+ week, 6+ day ago   (659+ words) Takeda Pharmaceutical’s Mimrylo is now approved for treating polycythemia vera, a rare blood cancer with limited therapeutic options. Originally developed by Protagonist Therapeutics, the engineered peptide gives Takeda a drug with blockbuster sales potential as the pharma company’s top overall…...

2+ week, 2+ day ago   (255+ words) Roivant Sciences subsidiary Priovant Therapeutics received FDA approval for Lisraya as a treatment for the rare inflammatory disorder dermatomyositis. Licensed from Pfizer, this once-daily pill designed to block JAK1 and TYK2 proteins is also in clinical development for three additional rare immunological…...

3+ week, 20+ hour ago   (771+ words) Abcuro will apply the capital to a study that could support a biologics license application in inclusion body myositis, a rare inflammatory disorder that leads to worsening muscle weakness. A Phase 2/3 study failed earlier this year, but Abcuro saw positive…...

3+ week, 2+ day ago   (240+ words) Along with Ambros Therapeutics’ merger with Werewolf Therapeutics, the combined company will raise $150 million in a private placement. Ambros is in Phase 3 testing with a drug developed for treating a type of pain that does not respond to currently available…...

3+ week, 6+ day ago   (298+ words) Migraine drugs developer Slate Medicines is going public in a reverse merger with Fulcrum Therapeutics. The biotech’s lead antibody drug blocks two novel migraine targets, offering the potential for better efficacy compared to other next-generation migraine drugs in R&D. When…...